Board of Directors – Extensive drug development & commercialization experience

Patrick Machado

Independent Director and Chair

30 years’ experience in the biotech sector and a deep understanding of the scientific and regulatory processes involved in bringing new treatments to market, served on boards of approximately 20 biotechnology companies across the U.S., Canada, Europe and Australia, four of which were sold to major pharma companies.

Dr. Paul Kelly

Director

(OneVentures Founding Partner, Series A lead investor)

Biotechnology entrepreneur, 30+ years experience in developing and commercialising biomedical innovations in US, EU, UK and Australia, led a Nasdaq IPO and merger (Nasdaq:GMNI, SQNM), clinician researcher with 100+ scientific publications.

PROF. MIMI TANG

Director

Global thought leader in allergy, clinician scientist with 25+ years’ experience as a pediatric allergist immunologist. Head of a research program examining the immune mechanisms driving allergic disease, that led to the development of Prota’s technology.

ADAM DEUTSCH

Director

(SPRIM Global Investments, Series A1 lead investor)

20+ years’ financial markets experience in Asia, UK/Europe and Australia, working for investment banks, private banks and specialist Emerging Market and SME focused firms. Specialist Biotech structured financing.

Thomas Fratacci

Director

(SPRIM Global Investments)

Group CFO of SPRIM and SPRIM Ventures, responsible for all finance functions within the Group and for developing robust business models to support financing rounds and exits. Thomas participated in the early years of SPRIM’s development, both in Asia and the US. He has 20 years of experience in corporate finance and business management in B2B environments.

Guillaume Pfefer

Director

Guillaume is Director of Prota Therapeutics. He has more than 25 years of experience in the pharmaceutical industry as senior executive of large global pharmaceutical companies and CEO of Biotech. His skill sets range across R&D, manufacturing, commercialization, P&L management, strategy, business development, financing and operations.